Oppenheimer Maintains Outperform on Madrigal Pharmaceuticals, Raises Price Target to $320
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Jay Olson has maintained an Outperform rating on Madrigal Pharmaceuticals (MDGL) and increased the price target from $300 to $320.
March 01, 2024 | 4:15 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer analyst Jay Olson reaffirmed an Outperform rating on Madrigal Pharmaceuticals and raised the price target to $320 from $300.
The increase in price target by a reputable analyst suggests a positive outlook on the company's future performance, likely leading to increased investor confidence and potentially driving the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100